Sagiru Hamza Abdullahi

ORCID, self-asserted

ORCID 0000-0002-2976-9636

Publications

Citations

277

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

15 works in the graph, newest first.

DFT and molecular dynamics exploration of 2-[2-(hydroxybenzylidene)amino]benzoic acid, and (2-hydroxybenzylidene)-(2-hydroxyphenyl)amine Schiff bases as green corrosion inhibitors for mild steel
2026Discover Chemistry.JournalOpen accessSenior author1 citations10.1007/s44371-026-00489-9
In Silico evaluation of naphthalene-based tubulin inhibitors as potential anticancer agents targeting breast cancer cells
2026Scientific AfricanJournalOpen accessFirst authorCorresponding0 citations10.1016/j.sciaf.2026.e03402
Unveiling novel VEGFR-2 inhibitors: QSAR modeling, molecular docking, MD and MM-GBSA calculations, pharmacokinetics profiling and DFT studies
2025Scientific AfricanJournalOpen accessFirst authorCorresponding3 citations10.1016/j.sciaf.2025.e02692
Design of some phthalazine molecules as novel VEGFR-2 target inhibitors through 3D-QSAR modeling, molecular docking and dynamic simulation and pharmacokinetics profiling
2024Journal of Umm Al-Qura University for Applied SciencesJournalOpen accessCorresponding3 citations10.1007/s43994-024-00197-z
Design of novel BRC1A target inhibitors: Docking simulation, QSAR modeling, MD simulation and Pharmacokinetics profiling
2024Scientific AfricanJournalOpen accessFirst authorCorresponding2 citations10.1016/j.sciaf.2024.e02522
Molecular docking studies of some benzoxazole and benzothiazole derivatives as VEGFR-2 target inhibitors: In silico design, MD simulation, pharmacokinetics and DFT studies
2023Intelligent PharmacyJournalOpen accessFirst authorCorresponding49 citations10.1016/j.ipha.2023.11.010
Pharmacokinetic profiling of quinazoline-4(3H)-one analogs as EGFR inhibitors: 3D-QSAR modeling, molecular docking studies and the design of therapeutic agents
2023Journal of Taibah University Medical SciencesJournalOpen accessFirst authorCorresponding20 citations10.1016/j.jtumed.2023.02.015
Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling
2023Journal of the Egyptian National Cancer InstituteJournalOpen accessFirst authorCorresponding19 citations10.1186/s43046-023-00182-3
2D and 3D-QSAR Modeling of 1H‑Pyrazole Derivatives as EGFR Inhibitors: Molecular Docking, and Pharmacokinetic Profiling
2023Chemistry AfricaJournalFirst authorCorresponding16 citations10.1007/s42250-023-00592-9
Computational design of quinoxaline molecules as VEGFR-2 inhibitors: QSAR modelling, pharmacokinetics, molecular docking, and dynamics simulation studies
2023Biocatalysis and Agricultural BiotechnologyJournalFirst authorCorresponding16 citations10.1016/j.bcab.2023.102787
In-silico design of some pyrazolopyridine analogs as breast cancer inhibitors: QSAR modeling, molecular docking, MD simulation, and pharmacological features profiling
2023Journal of the Indian Chemical SocietyJournalFirst authorCorresponding8 citations10.1016/j.jics.2023.101053
In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line
2022Bulletin of the National Research Centre/Bulletin of the National Research CenterJournalOpen accessFirst authorCorresponding59 citations10.1186/s42269-021-00690-z
Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents
2022Bulletin of the National Research Centre/Bulletin of the National Research CenterJournalOpen accessFirst authorCorresponding39 citations10.1186/s42269-022-00869-y
Molecular Docking , ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors
2022Egyptian Journal of Basic and Applied SciencesJournalOpen accessFirst authorCorresponding27 citations10.1080/2314808x.2022.2050115
Structure Based Design of Some Novel 3-Methylquinoxaline Derivatives Through Molecular Docking and Pharmacokinetics Studies as Novel VEGFR-2 Inhibitors
2022Chemistry AfricaJournalFirst authorCorresponding15 citations10.1007/s42250-022-00485-3